Phase II trial: Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer patients.

医学 中性粒细胞减少症 放射治疗 食管炎 内科学 化疗 肺癌 多西紫杉醇 恶心 顺铂 肿瘤科 临床研究阶段 性能状态 胃肠病学 外科 泌尿科 疾病 回流
作者
Dolores de la Mata,M. Blake,J. Zamora Moreno,Omar Pena,Diana Flores‐Estrada,J. Turcott,Óscar Arrieta
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:30 (15_suppl): 7068-7068
标识
DOI:10.1200/jco.2012.30.15_suppl.7068
摘要

7068 Background: The treatment of choice for locally advanced non small cell lung cancer (NSCLC) is concurrent chemoradiation (CRT). However, efforts to improve treatment results include targeted therapy and the use of radiosensitizers. Nitroglycerin (NTG), a nitric oxide (NO) donor agent, reduces expression of Hypoxia-Induced Factor, which is associated to both chemo and radio resistance. Methods: This is phase II trial in patients with locally advanced NSCLC treated with chemotherapy (CT) based on cisplatin and vinorelbin with NTG concurrent with radiation therapy. A 25 mg NTG patch was administered to the patients during the first 5 days of each induction treatment cycle and during chemo-radiotherapy. Blood samples of VEGF were taken before any treatment and after two cycles of CT. The protocol is registered with ClinicalTrials.gov, number NCT00886405. Results: 35 patients were enrolled in this trial. Median Follow up was 16.6 months (SD ±13.6). Mean age was of 59.9 years (±10.8), 68.6% of the patients were smokers. ECOG status was 0 in 22.9%, 1 in 65.7% and 2 in 11.5%, respectively. Histopathology was adenocarcinoma in 68.6%, epidermoid in 17.1% and undifferentiated in 14.3%. Stage distribution was: IIIa, 57.6% and IIIb, 42.5%. All patients completed CRT treatment and four underwent surgical treatment. Toxicity profile related to NTG was grade 1 and 2 headache in 17.1%. Grade 3 and 4 toxicities were esophagitis (17.1%), neutropenia (62.9%), and nausea (5.7%). Sixty-four per cent of patients achieved partial response after CT and 75.8% after CRT. PFS was 11.8 months (95%, IC 7.8-15.6) and OS was 42.9 months (95%IC 31.3-52.1). After two cycles of CT, plasma VEGF levels were significantly lower (Median 132±79 vs. 53±78 pg/ml, p<0.001). No differences on PFS and OS were found between patients with a reduction ≥ 93 pg/ml (median of differences between VEGFR before and after chemotherapy). Conclusions: The addition of NTG to induction CT, and concurrent CRT on locally advanced NSCLC patients seems to increase the response rate, PFS and OS with an acceptable toxicity profile. A prospective trial is warranted to confirm these findings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sofia发布了新的文献求助10
刚刚
1秒前
体贴的青烟完成签到,获得积分10
1秒前
脑洞疼应助小猪哄哄采纳,获得10
2秒前
Chengcheng发布了新的文献求助10
2秒前
霸气向日葵完成签到,获得积分10
2秒前
4秒前
dumeng发布了新的文献求助10
4秒前
cholate关注了科研通微信公众号
5秒前
研究啥发布了新的文献求助30
6秒前
6秒前
mashichuang发布了新的文献求助10
8秒前
8秒前
vincy完成签到 ,获得积分10
8秒前
9秒前
脑洞疼应助潇洒夏山采纳,获得10
9秒前
caicai完成签到,获得积分10
10秒前
点点发布了新的文献求助30
11秒前
12秒前
13秒前
13秒前
13秒前
14秒前
WIsh完成签到 ,获得积分10
14秒前
自由飞翔完成签到,获得积分10
14秒前
16秒前
16秒前
研友_VZG7GZ应助学术悍匪采纳,获得10
18秒前
cholate发布了新的文献求助10
18秒前
ydfqlzj发布了新的文献求助10
20秒前
爱lx发布了新的文献求助10
21秒前
21秒前
鲤鱼香之完成签到,获得积分10
21秒前
22秒前
sofia完成签到,获得积分20
24秒前
ping发布了新的文献求助10
25秒前
哪吒完成签到,获得积分20
26秒前
26秒前
27秒前
Akim应助橙子采纳,获得10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976267
求助须知:如何正确求助?哪些是违规求助? 3520472
关于积分的说明 11203425
捐赠科研通 3257089
什么是DOI,文献DOI怎么找? 1798589
邀请新用户注册赠送积分活动 877785
科研通“疑难数据库(出版商)”最低求助积分说明 806523